Cargando…

Increased depression and metabolic risk in postmenopausal breast cancer survivors

OBJECTIVE: Breast cancer survivors (BCS) are at high risk for the development of obesity, type 2 diabetes mellitus, and metabolic syndrome. There is increasing interest in the association between depression and metabolic dysfunction, which is relevant in this population as depression is often presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Serra, Monica C., Goldberg, Andrew P., Ryan, Alice S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957862/
https://www.ncbi.nlm.nih.gov/pubmed/27453736
http://dx.doi.org/10.1186/s13098-016-0170-4
_version_ 1782444239432450048
author Serra, Monica C.
Goldberg, Andrew P.
Ryan, Alice S.
author_facet Serra, Monica C.
Goldberg, Andrew P.
Ryan, Alice S.
author_sort Serra, Monica C.
collection PubMed
description OBJECTIVE: Breast cancer survivors (BCS) are at high risk for the development of obesity, type 2 diabetes mellitus, and metabolic syndrome. There is increasing interest in the association between depression and metabolic dysfunction, which is relevant in this population as depression is often present in the chronic phase of cancer recovery. Thus, the aim of this study was to evaluate metabolic risk in BCS with and without depression compared to non-cancer controls. METHODS: African American (46 %) and Caucasian (54 %) postmenopausal BCS (N = 28; age: 60 ± 2 years; mean ± SEM) were matched for race, age (±2 years), and BMI (±2 kg/m(2)) to non-cancer controls (N = 28). Center for Epidemiologic Studies Depression Scale (CES-D) >16 or antidepressant medication usage was used to classify depression. Metabolic status was defined by 2-hr glucose during an OGTT and classification of metabolic syndrome. RESULTS: Compared to non-cancer controls, BCS had similar 2-hr glucose, but higher fasting glucose and total cholesterol, and were 2.5 times more likely to have metabolic syndrome (21 vs. 52 %)(P’s < 0.05). Conversely, HDL-C was 16 % higher in BCS (P < 0.05). Forty three % of BCS were on antidepressants compared to 14 % in non-cancer controls, despite similar mean CES-D scores (6 ± 1). Depressed BCS (46 %) had a higher BMI, waist circumference, fasting glucose, and more metabolic syndrome components than non-depressed BCS (P’s < 0.05). CONCLUSIONS: BCS have a heightened prevalence of depression that may be associated with an increased prevalence of metabolic syndrome. These results support the need to monitor weight gain, depression, and the progression of metabolic abnormalities after cancer diagnosis and treatment. Further studies into the mechanistic link between depression and metabolic disease are necessary to identify strategies that can offset their impact on obesity and associated cardiovascular risk following a breast cancer diagnosis.
format Online
Article
Text
id pubmed-4957862
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49578622016-07-23 Increased depression and metabolic risk in postmenopausal breast cancer survivors Serra, Monica C. Goldberg, Andrew P. Ryan, Alice S. Diabetol Metab Syndr Research OBJECTIVE: Breast cancer survivors (BCS) are at high risk for the development of obesity, type 2 diabetes mellitus, and metabolic syndrome. There is increasing interest in the association between depression and metabolic dysfunction, which is relevant in this population as depression is often present in the chronic phase of cancer recovery. Thus, the aim of this study was to evaluate metabolic risk in BCS with and without depression compared to non-cancer controls. METHODS: African American (46 %) and Caucasian (54 %) postmenopausal BCS (N = 28; age: 60 ± 2 years; mean ± SEM) were matched for race, age (±2 years), and BMI (±2 kg/m(2)) to non-cancer controls (N = 28). Center for Epidemiologic Studies Depression Scale (CES-D) >16 or antidepressant medication usage was used to classify depression. Metabolic status was defined by 2-hr glucose during an OGTT and classification of metabolic syndrome. RESULTS: Compared to non-cancer controls, BCS had similar 2-hr glucose, but higher fasting glucose and total cholesterol, and were 2.5 times more likely to have metabolic syndrome (21 vs. 52 %)(P’s < 0.05). Conversely, HDL-C was 16 % higher in BCS (P < 0.05). Forty three % of BCS were on antidepressants compared to 14 % in non-cancer controls, despite similar mean CES-D scores (6 ± 1). Depressed BCS (46 %) had a higher BMI, waist circumference, fasting glucose, and more metabolic syndrome components than non-depressed BCS (P’s < 0.05). CONCLUSIONS: BCS have a heightened prevalence of depression that may be associated with an increased prevalence of metabolic syndrome. These results support the need to monitor weight gain, depression, and the progression of metabolic abnormalities after cancer diagnosis and treatment. Further studies into the mechanistic link between depression and metabolic disease are necessary to identify strategies that can offset their impact on obesity and associated cardiovascular risk following a breast cancer diagnosis. BioMed Central 2016-07-22 /pmc/articles/PMC4957862/ /pubmed/27453736 http://dx.doi.org/10.1186/s13098-016-0170-4 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Serra, Monica C.
Goldberg, Andrew P.
Ryan, Alice S.
Increased depression and metabolic risk in postmenopausal breast cancer survivors
title Increased depression and metabolic risk in postmenopausal breast cancer survivors
title_full Increased depression and metabolic risk in postmenopausal breast cancer survivors
title_fullStr Increased depression and metabolic risk in postmenopausal breast cancer survivors
title_full_unstemmed Increased depression and metabolic risk in postmenopausal breast cancer survivors
title_short Increased depression and metabolic risk in postmenopausal breast cancer survivors
title_sort increased depression and metabolic risk in postmenopausal breast cancer survivors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957862/
https://www.ncbi.nlm.nih.gov/pubmed/27453736
http://dx.doi.org/10.1186/s13098-016-0170-4
work_keys_str_mv AT serramonicac increaseddepressionandmetabolicriskinpostmenopausalbreastcancersurvivors
AT goldbergandrewp increaseddepressionandmetabolicriskinpostmenopausalbreastcancersurvivors
AT ryanalices increaseddepressionandmetabolicriskinpostmenopausalbreastcancersurvivors